{"url_path":"/sec/ibio/8-k/2026-07-01/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1420720/0001420720-26-000010-index.html","accession_number":"0001420720-26-000010","cik":"0001420720","ticker":"IBIO","issuer_name":"iBio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1420720/0001420720-26-000010-index.html","primary_entity_key":"0001420720","primary_entity_name":"iBio, Inc."},"word_count":207,"has_tables":true,"body_markdown":"**Item 8.01. Other Events.**\n\nOn July 1, 2026, the Company issued a press release announcing new preclinical data from its obese NHP study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate.\n\nFollowing a single dose of IBIO-610, active Activin E levels in the blood were reduced in all treated NHPs and remained suppressed through eight weeks. At both weeks 4 and 8, active Activin E levels were reduced to levels below the limits of the assay. Overall, active Activin E was reduced by 98% at week 4 and 97% at week 8 compared with baseline. These findings support IBIO-610's potential for best-in-class pathway inhibition and further support the potential for an infrequently dosed, long-acting antibody approach.\n\nThe data also demonstrated IBIO-610's potential to promote fat-selective weight loss while preserving lean mass. In obese NHPs, when combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone, further supporting its potential as both a stand-alone therapy and a complementary approach to GLP-1-based treatments.\n\nThe full data will be highlighted in a presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes, taking place September 28 – October 2 in Milan, Italy.\n\n​"}